Suppr超能文献

解决美沙酮类物质处方障碍的政策途径。

Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

机构信息

Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan.

Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan; Center for Clinical Management Research, Department of Veterans Affairs, Ann Arbor, Michigan.

出版信息

Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242. doi: 10.1016/j.amepre.2017.12.022.

Abstract

UNLABELLED

At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include providing free and easy-to-access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types-including behavioral health counselors and other non-physicians in specialty and non-specialty settings.

SUPPLEMENT INFORMATION

This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.

摘要

未加标签

美国至少有 230 万人患有阿片类药物使用障碍,但只有不到 40%的人接受循证治疗。作为药物辅助治疗的一部分,丁丙诺啡具有很高的潜力来解决这一差距,因为它被批准用于非专科门诊环境,有效促进戒除毒瘾,并且具有成本效益。然而,只有不到 4%的持照医生被批准开具丁丙诺啡治疗阿片类药物使用障碍,大约 47%的县没有丁丙诺啡豁免医生。现有政策造成了丁丙诺啡提供和获取方面的劳动力障碍。由于劳动力障碍,提供者不愿意开丁丙诺啡,这些障碍包括:(1)在阿片类药物使用障碍治疗方面的培训和教育不足;(2)缺乏机构和临床医生同行的支持;(3)医疗协调不善;(4)提供者耻辱感;(5)私人和公共保险公司的报销不足;(6)获得在非成瘾专科治疗环境中开具丁丙诺啡所需豁免的监管障碍。解决这些提供者劳动力障碍的政策途径包括为提供者提供关于阿片类药物使用障碍和药物辅助治疗的免费且易于获取的教育,取消对有资格开具受控物质的人的丁丙诺啡豁免要求,执行保险均等要求,将基于证据的药物辅助治疗作为基本健康福利进行覆盖,并为医疗协调提供财务激励,包括行为健康顾问和其他在专科和非专科环境中的非医师。

补充信息

本文是题为“行为健康劳动力:规划、实践和准备”的补充内容的一部分,该补充内容由美国卫生与公众服务部下属的物质滥用和精神卫生服务管理局以及卫生资源和服务管理局赞助。

相似文献

1
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242. doi: 10.1016/j.amepre.2017.12.022.
2
Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine.
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S208-S214. doi: 10.1016/j.amepre.2018.02.006.
4
Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
Ann Fam Med. 2017 Jul;15(4):359-362. doi: 10.1370/afm.2099.
5
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
8

引用本文的文献

3
Receipt of medications for opioid use disorder among rural and urban veterans health administration patients.
Drug Alcohol Depend Rep. 2024 Dec 14;14:100311. doi: 10.1016/j.dadr.2024.100311. eCollection 2025 Mar.
6
Barriers in Office-Based Opioid Treatment in Rural United States.
Cureus. 2024 Nov 10;16(11):e73373. doi: 10.7759/cureus.73373. eCollection 2024 Nov.
10
How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain.
J Clin Oncol. 2025 Jan;43(1):10-14. doi: 10.1200/JCO.24.00705. Epub 2024 Sep 17.

本文引用的文献

4
Primary care models for treating opioid use disorders: What actually works? A systematic review.
PLoS One. 2017 Oct 17;12(10):e0186315. doi: 10.1371/journal.pone.0186315. eCollection 2017.
5
Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015.
MMWR Morb Mortal Wkly Rep. 2017 Jul 7;66(26):697-704. doi: 10.15585/mmwr.mm6626a4.
6
The Role of Science in Addressing the Opioid Crisis.
N Engl J Med. 2017 Jul 27;377(4):391-394. doi: 10.1056/NEJMsr1706626. Epub 2017 May 31.
8
Access to treatment for opioid use disorders: Medical student preparation.
Am J Addict. 2017 Jun;26(4):316-318. doi: 10.1111/ajad.12550. Epub 2017 Apr 10.
9
Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids.
JAMA. 2017 Mar 7;317(9):967-968. doi: 10.1001/jama.2017.0001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验